In this ovarian cancer journal scan, our panel reviews:
1) The results of the randomised phase III GOG-0213 study that involved patients with platinum-sensitive, recurrent epithelial ovarian cancer, secondary surgical cytoreduction followed by chemotherapy.
2) The Food and Drug Administration approval of niraparib (ZEJULA, GlaxoSmithKline) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, regardless of biomarker status.
3) The randomized Phase II Trial of Nivolumab vs. Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer
Coleman RL, et al. N Engl J Med. 2019.
BJ Rimel, MD
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
N Engl J Med . 2019 Dec 19;381(25):2391-2402.
Brian Slomovitz, MD
Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study
J Clin Oncol . 2020 Jun 1;38(16):1814-1823.
Thomas Herzog, MD
Research teams unite to develop an early detection test for ovarian cancer.
Cancer. 2020 May 15;126(10):2113
Expanding use of rucaparib as maintenance therapy in recurrent ovarian cancer: updates from the ARIEL3 trial.
Lancet Oncol. 2020 May;21(5):616-617
DGKA provides platinum resistance in ovarian cancer through activation of cJUN-WEE1 signaling.
Clin Cancer Res. 2020 Apr 27;:
Global Team of Cancer Genetic Specialists Provides New Guidance for Individuals with PALB2 Gene Variants: ACMG Clinical Practice Resource to Help Guide Clinical Management of Patients at Increased Risk of Breast, Pancreatic and Ovarian Cancers
May 11, 2021
(ACMG) May 11, 2021 - The American College of Medical Genetics and Genomics (ACMG) has released an important new clinical practice resource from a ...
New Drug Class Gives Hope To Some Ovarian Cancer Patients
May 04, 2021
(UW Medicine) May 3, 2021 - A study published today shows that the drug rucaparib has been effective in treating certain types of ovarian cancers i...
Mereo BioPharma and Cancer Focus Fund Announce Partnership for Phase 1b/2 Study of Etigilimab in Clear Cell Ovarian Cancer
April 30, 2021
(Yahoo! Finance) Apr 30, 2021 - Mereo BioPharma Group plc and Cancer Focus Fund, LP, a unique venture capital fund established in collaboration wit...
Drug Derived from Kentucky-Grown Plant Shows Promise for Ovarian Cancer Treatment, Study Shows
April 27, 2021
(UK Healthcare) Apr 20, 2021 - A new study from University of Kentucky Markey Cancer researchers shows that Artemisia annua, a plant that has been ...
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
April 27, 2021
(Markets Insider) Apr 27, 2021 - U.S. FDA granted Fast Track Designation in 2018. Trial expected to enroll 300-400 patients at approximately 165 S...